Di Zhu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Di Zhu has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Cheng Shen
Shaanxi Key Laboratory of Natural Products & Chemical Biology, College of Chemistry & Pharmacy, Northwest A&F University, Yangling, Shaanxi, China
16 shared publications - Fanghui Lu
Institute of Life Sciences, Chongqing Medical University, Chongqing, China
16 shared publications - Haiyang Li
The Research Center of Chiral Drugs, Innovation Research Institute of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China
16 shared publications - Jianbo Pan
Basic Medicine Research and Innovation Center for Novel Target and Therapeutic Intervention, Ministry of Education, College of Pharmacy, Chongqing Medical University, Chongqing 400016, China
16 shared publications - Jiang-Jiang Tang
College of Chemistry & Pharmacy, Northwest A&F University, Yangling 712100, China
16 shared publications - Jianjun Fan
Basic Medicine Research and Innovation Center for Novel Target and Therapeutic Intervention, Ministry of Education, Institute of Life Sciences, the Second Affiliated Hospital of Chongqing Medical University, Chongqing Medical University, Chongqing 400010, China
16 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Legends and Table S1 from The Antipsychotic Drug Penfluridol Inhibits N-Linked Glycoprotein Processing and Enhances T-cell–Mediated Tumor Immunity
Supplementary Figure S1-S4 Supplementary Table S1
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Legends and Table S1 from The Antipsychotic Drug Penfluridol Inhibits N-Linked Glycoprotein Processing and Enhances T-cell–Mediated Tumor Immunity
Supplementary Figure S1-S4 Supplementary Table S1
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from The Antipsychotic Drug Penfluridol Inhibits N-Linked Glycoprotein Processing and Enhances T-cell–Mediated Tumor Immunity
(a) Western blot analysis of glycoprotein patterns in MDA-MB-231 cells after treatment with the indicated concentrations of penfluridol for 24 hours. Red arrowhead, immature glycoproteins. (b) Western blot analysis of protein expression pattern of ACE2 in HEK293T cells after treatment with the indicated concentrations of penfluridol for 24 hours. (c) In HEK293T cells, FLAG-tagged ACE2 was treated for 24 hours, collected by immunoprecipitation, subjected to SDS-PAGE, and analyzed by western blot. (d) Pearson correlation coefficient of three independent groups of (c) through N-glycan profiling.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from The Antipsychotic Drug Penfluridol Inhibits N-Linked Glycoprotein Processing and Enhances T-cell–Mediated Tumor Immunity
(a) Western blot analysis of glycoprotein patterns in MDA-MB-231 cells after treatment with the indicated concentrations of penfluridol for 24 hours. Red arrowhead, immature glycoproteins. (b) Western blot analysis of protein expression pattern of ACE2 in HEK293T cells after treatment with the indicated concentrations of penfluridol for 24 hours. (c) In HEK293T cells, FLAG-tagged ACE2 was treated for 24 hours, collected by immunoprecipitation, subjected to SDS-PAGE, and analyzed by western blot. (d) Pearson correlation coefficient of three independent groups of (c) through N-glycan profiling.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from The Antipsychotic Drug Penfluridol Inhibits N-Linked Glycoprotein Processing and Enhances T-cell–Mediated Tumor Immunity
(a) The stability of proteins was determined by cellular thermal shift at different concentrations of penfluridol.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from The Antipsychotic Drug Penfluridol Inhibits N-Linked Glycoprotein Processing and Enhances T-cell–Mediated Tumor Immunity
(a) The stability of proteins was determined by cellular thermal shift at different concentrations of penfluridol.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from The Antipsychotic Drug Penfluridol Inhibits N-Linked Glycoprotein Processing and Enhances T-cell–Mediated Tumor Immunity
(a) Western blot analysis of protein expression pattern of PD-L1 in HEK293T cells after the exposure to the indicated concentrations of penfluridol for 24 hours. (b) Protein expression pattern of PD-L1 in B16-F10 cells after treatment with the indicated concentrations of penfluridol for 12 hours as determined by western blot. (c) The toxicity effect of penfluridol on B16-F10 (top) and B16-OVA (bottom) cells. (d) Western blot analysis of protein expression of MAN1A1 in B16-OVA cells treated with the indicated siRNA.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from The Antipsychotic Drug Penfluridol Inhibits N-Linked Glycoprotein Processing and Enhances T-cell–Mediated Tumor Immunity
(a) Western blot analysis of protein expression pattern of PD-L1 in HEK293T cells after the exposure to the indicated concentrations of penfluridol for 24 hours. (b) Protein expression pattern of PD-L1 in B16-F10 cells after treatment with the indicated concentrations of penfluridol for 12 hours as determined by western blot. (c) The toxicity effect of penfluridol on B16-F10 (top) and B16-OVA (bottom) cells. (d) Western blot analysis of protein expression of MAN1A1 in B16-OVA cells treated with the indicated siRNA.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from The Antipsychotic Drug Penfluridol Inhibits N-Linked Glycoprotein Processing and Enhances T-cell–Mediated Tumor Immunity
(a) qPCR analysis of the GRP78 and CHOP expression in MDA-MB-231 cells after the treatment with the indicated concentrations for 6 hours. (b) Western blot analysis of Integrin β1 expression pattern in MDA-MB-231 cells after indicated drugs treatment for 24 hours. (c) Western blot analysis of protein expression pattern of Integrin β1 in MDA-MB-231 cells treated with the indicated siRNA.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from The Antipsychotic Drug Penfluridol Inhibits N-Linked Glycoprotein Processing and Enhances T-cell–Mediated Tumor Immunity
(a) qPCR analysis of the GRP78 and CHOP expression in MDA-MB-231 cells after the treatment with the indicated concentrations for 6 hours. (b) Western blot analysis of Integrin β1 expression pattern in MDA-MB-231 cells after indicated drugs treatment for 24 hours. (c) Western blot analysis of protein expression pattern of Integrin β1 in MDA-MB-231 cells treated with the indicated siRNA.
- Open Access
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from The Antipsychotic Drug Penfluridol Inhibits N-Linked Glycoprotein Processing and Enhances T-cell–Mediated Tumor Immunity
(a) The stability of proteins was determined by cellular thermal shift at different concentrations of penfluridol.
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from The Antipsychotic Drug Penfluridol Inhibits N-Linked Glycoprotein Processing and Enhances T-cell–Mediated Tumor Immunity
(a) The stability of proteins was determined by cellular thermal shift at different concentrations of penfluridol.
- Open Access
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from The Antipsychotic Drug Penfluridol Inhibits N-Linked Glycoprotein Processing and Enhances T-cell–Mediated Tumor Immunity
(a) qPCR analysis of the GRP78 and CHOP expression in MDA-MB-231 cells after the treatment with the indicated concentrations for 6 hours. (b) Western blot analysis of Integrin β1 expression pattern in MDA-MB-231 cells after indicated drugs treatment for 24 hours. (c) Western blot analysis of protein expression pattern of Integrin β1 in MDA-MB-231 cells treated with the indicated siRNA.
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from The Antipsychotic Drug Penfluridol Inhibits N-Linked Glycoprotein Processing and Enhances T-cell–Mediated Tumor Immunity
(a) qPCR analysis of the GRP78 and CHOP expression in MDA-MB-231 cells after the treatment with the indicated concentrations for 6 hours. (b) Western blot analysis of Integrin β1 expression pattern in MDA-MB-231 cells after indicated drugs treatment for 24 hours. (c) Western blot analysis of protein expression pattern of Integrin β1 in MDA-MB-231 cells treated with the indicated siRNA.
- Open Access
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from The Antipsychotic Drug Penfluridol Inhibits N-Linked Glycoprotein Processing and Enhances T-cell–Mediated Tumor Immunity
(a) The stability of proteins was determined by cellular thermal shift at different concentrations of penfluridol.
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from The Antipsychotic Drug Penfluridol Inhibits N-Linked Glycoprotein Processing and Enhances T-cell–Mediated Tumor Immunity
(a) The stability of proteins was determined by cellular thermal shift at different concentrations of penfluridol.
- Open Access
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Legends and Table S1 from The Antipsychotic Drug Penfluridol Inhibits N-Linked Glycoprotein Processing and Enhances T-cell–Mediated Tumor Immunity
Supplementary Figure S1-S4 Supplementary Table S1
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Legends and Table S1 from The Antipsychotic Drug Penfluridol Inhibits N-Linked Glycoprotein Processing and Enhances T-cell–Mediated Tumor Immunity
Supplementary Figure S1-S4 Supplementary Table S1
- Open Access
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from The Antipsychotic Drug Penfluridol Inhibits N-Linked Glycoprotein Processing and Enhances T-cell–Mediated Tumor Immunity
(a) Western blot analysis of protein expression pattern of PD-L1 in HEK293T cells after the exposure to the indicated concentrations of penfluridol for 24 hours. (b) Protein expression pattern of PD-L1 in B16-F10 cells after treatment with the indicated concentrations of penfluridol for 12 hours as determined by western blot. (c) The toxicity effect of penfluridol on B16-F10 (top) and B16-OVA (bottom) cells. (d) Western blot analysis of protein expression of MAN1A1 in B16-OVA cells treated with the indicated siRNA.
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from The Antipsychotic Drug Penfluridol Inhibits N-Linked Glycoprotein Processing and Enhances T-cell–Mediated Tumor Immunity
(a) Western blot analysis of protein expression pattern of PD-L1 in HEK293T cells after the exposure to the indicated concentrations of penfluridol for 24 hours. (b) Protein expression pattern of PD-L1 in B16-F10 cells after treatment with the indicated concentrations of penfluridol for 12 hours as determined by western blot. (c) The toxicity effect of penfluridol on B16-F10 (top) and B16-OVA (bottom) cells. (d) Western blot analysis of protein expression of MAN1A1 in B16-OVA cells treated with the indicated siRNA.